Exelixis To Investors: "Wait For It... No, Seriously, Wait For It!"
Small-cap biopharmaceutical company Exelixis (NASDAQ:EXEL) sent a simple message to investors this past week: "Wait for it... No, seriously, wait for it."
Exelixis' holding pattern
The second-half of 2015 was supposed to bring a number of catalysts for Exelixis and its shareholders. One was the Food and Drug Administration's expected decision on approval of the combination of Exelixis' cobimetinib and Roche's Zelboraf as a treatment for BRAF V600 mutation-positive metastatic melanoma. The combination therapy garnered a priority review from the FDA, shortening the review process from the standard 10 months to six months and carrying a PDUFA date (i.e., an FDA decision date) of Aug. 11, 2015.
Hey, check out all the research scientist jobs. Post your resume today!
Exelixis' holding pattern
The second-half of 2015 was supposed to bring a number of catalysts for Exelixis and its shareholders. One was the Food and Drug Administration's expected decision on approval of the combination of Exelixis' cobimetinib and Roche's Zelboraf as a treatment for BRAF V600 mutation-positive metastatic melanoma. The combination therapy garnered a priority review from the FDA, shortening the review process from the standard 10 months to six months and carrying a PDUFA date (i.e., an FDA decision date) of Aug. 11, 2015.
Hey, check out all the research scientist jobs. Post your resume today!